Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GR | ISIN: US4510337086 | Ticker-Symbol: 0JV0
NASDAQ
25.06.25 | 22:00
0,730 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IBIO INC Chart 1 Jahr
5-Tage-Chart
IBIO INC 5-Tage-Chart

Aktuelle News zur IBIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05:22Pharos iBio Receives IND Approval for PHI-501 Phase 1 Trial3
DiiBio stock soars after amylin receptor antibody shows promising results1
DiiBio, Inc.: iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results5
MoiBio veranstaltet Telefonkonferenz zu Fortschritten bei Adipositas-Behandlung6
MoiBio to host conference call on obesity treatment advances4
18.06.iBio, Inc. - 8-K, Current Report5
IBIO Aktie jetzt für 0€ handeln
05.05.iBio, Inc.: iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model4
02.05.iBio, Inc. - 10-Q, Quarterly Report2
02.05.iBio GAAP EPS of -$0.49 misses by $0.243
02.05.iBio, Inc. - 8-K, Current Report1
02.05.iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results223SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress....
► Artikel lesen
29.04.iBio secures $6.2 million through warrant exercise2
29.04.iBio sichert sich 6,2 Millionen US-Dollar durch Optionsscheinausübung1
29.04.iBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement Transaction138SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered...
► Artikel lesen
22.04.iBio, Inc. - 8-K, Current Report12
22.04.iBio, Inc.: iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio8
07.04.iBio reports promising data on obesity treatment antibody8
07.04.iBio, Inc.: iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline215Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo...
► Artikel lesen
07.04.iBio, Inc. - 8-K, Current Report2
03.03.iBio, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities8
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1